| 6 -0.02 (-0.33%) | 06-09 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.56 | 1-year : | 8.84 |
| Resists | First : | 6.48 | Second : | 7.56 |
| Pivot price | 5.96 |
|||
| Supports | First : | 5.76 | Second : | 5.32 |
| MAs | MA(5) : | 5.96  |
MA(20) : | 5.91 |
| MA(100) : | 5.87 |
MA(250) : | 7 |
|
| MACD | MACD : | -0.1 |
Signal : | -0.1 |
| %K %D | K(14,3) : | 49.7 |
D(3) : | 49.7 |
| RSI | RSI(14): 49.6 |
|||
| 52-week | High : | 11.53 | Low : | 4.5 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ ACOG ] has closed below upper band by 44.4%. Bollinger Bands are 47.8% narrower than normal. The narrow width of the bands suggests low volatility as compared to its normal range. The bands have been in this narrow range for 4 bars. This is a sign that the market may be about to initiate a new trend.
| If tomorrow: | Open lower | Open higher |
| High: | 6.12 - 6.15 | 6.15 - 6.18 |
| Low: | 5.8 - 5.84 | 5.84 - 5.88 |
| Close: | 5.93 - 6 | 6 - 6.06 |
Alpha Cognition Inc. is a clinical-stage biopharmaceutical firm focused on creating therapies for neurological conditions such as Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). Among its offerings is ZUNVEYL (benzgalantamine), intended for the management of mild-to-moderate Alzheimer's disease and mild traumatic brain injury. The company is also progressing with other therapeutic programs, including ALPHA-0602, a gene therapy specifically for ALS, and ALPHA-0702 and ALPHA-0802, which are granulin epithelin motifs targeting various neurodegenerative disorders. Founded in 2000, the company initially operated as Crystal Bridge Enterprises Inc. before rebranding to Alpha Cognition Inc. in March 2021. Its corporate base is located in Vancouver, Canada.
Sat, 02 May 2026
When Will Alpha Cognition Inc. (NASDAQ:ACOG) Turn A Profit? - simplywall.st
Thu, 26 Mar 2026
ALPHA COGNITION ($ACOG) Releases Q4 2025 Earnings | ACOG Stock News - Quiver Quantitative
Fri, 16 Jan 2026
Insider Traders Lose US$128k As Alpha Cognition Drops - simplywall.st
Tue, 06 Jan 2026
Hedge funds own 20% of Alpha Cognition Inc. (NASDAQ:ACOG) shares but individual investors control 53% of the company - Yahoo Finance
Fri, 25 Apr 2025
ACOG Stock Price, News & Analysis | Alpha Cognition - Stock Titan
Sat, 11 Jan 2025
Should I buy Alpha Cognition Inc. (ACOG) - Zacks Investment Research
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Financial Services
|
|
|
Industry:
Financial - Conglomerates
|
|
| Shares Out | 22 (M) |
| Shares Float | 12 (M) |
| Held by Insiders | 6.5 (%) |
| Held by Institutions | 52.8 (%) |
| Shares Short | 189 (K) |
| Shares Short P.Month | 205 (K) |
| EPS | -1.39 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.64 |
| Profit Margin | -234.9 % |
| Operating Margin | -229.2 % |
| Return on Assets (ttm) | -29.1 % |
| Return on Equity (ttm) | -51.8 % |
| Qtrly Rev. Growth | 20.7 % |
| Gross Profit (p.s.) | 0.43 |
| Sales Per Share | 0.49 |
| EBITDA (p.s.) | -1.26 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -21 (M) |
| PE Ratio | -4.32 |
| PEG Ratio | 0 |
| Price to Book value | 2.27 |
| Price to Sales | 12.06 |
| Price to Cash Flow | -4.34 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|